The erythema migrans (EM) rash, when present, is often the first clinical sign of Lyme disease. This study shows that EM presentations vary with age, sex, EM duration, body location, and timing of initiation of antibiotics. Understanding this EM variability can help physicians and the general public better recognize the rash and improve early diagnosis and treatment.
This study examines heterogeneity in symptom reporting in patients with well-defined post treatment Lyme disease (PTLD) in order to identify and characterize clinically relevant patient subgroups.
Objective metabolite-based measurements differ between Lyme disease patients that develop persistent symptoms following antibiotic treatment (PTLD) and those that are clinically cured. These differences could be useful in better identifying, differentiating, and understanding the underlying biochemistry of patients with persistent symptoms in Lyme disease.
Lyme disease infection and genetic susceptibility to autoimmune diseases may trigger breakdown in tolerance to self-antigens & contribute to dysregulated immunity, autoimmune illness, & persistent symptoms
Summary This study shows that artificial intelligence (AI) and deep learning (DL) methods can be used to analyze cell phone rash images to more accurately detect and prescreen the erythema […]
Summary The aim of this paper is to review the current literature on the diagnosis, etiology, risk factors, treatments and heterogeneity of patients with persistent symptoms of Lyme disease. The […]
